5442102026-07-035442102026-07-032026-07-035442102026-07-03in-capmkt:FinancialYear1Member5442102026-07-03in-capmkt:FinancialYear2Member5442102026-07-03in-capmkt:FinancialYear3Member5442102026-07-032026-07-03in-capmkt:FinancialYear1Member5442102026-07-032026-07-03in-capmkt:FinancialYear2Member5442102026-07-032026-07-03in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure544210Emcure Pharmaceuticals LimitedEMCURENOTLISTEDINE168P01015NewAcquisition (including agreement to acquire)false2026-07-0220:00:002026-07-03Marcan Pharmaceuticals Inc.SubsidiaryMantra Pharma Inc.618010000078700000450000000falsetrueThe CFO of listed entity is a Director of the subsidiary.truePharmaceuticalsIn accordance with the terms of the Preferred Share Purchase Agreements entered into during the acquisition of Mantra as described in point ‘j’ of the intimation, Marcan is purchasing all of the Preferred shares i.e., Class E Special Shares from certain shareholders of Mantra.NAfalseJuly 03, 2026Cash3363000000Cash3363000000111Mantra, a wholly owned subsidiary of Marcan Pharmaceuticals Inc. (“Marcan”) was formed on November 06, 2023 under the Business Corporation Act (Quebec) by amalgamation between 9501-2969 Québec Inc. (a company incorporated and capitalized by Marcan on October 16, 2023), Mantra Pharma Inc. (erstwhile Mantra), Myriad Pharma Inc., Mantra Distribution Inc., Holding JFL Inc., Gestion Nirdac Inc., Gestion Stéphane Turcotte Inc., Gestion Beflan Inc. and Gestion Éléoraph Inc. The company operates primarily in the Canadian market.2025-202661801000002024-202549231000002023-20241734500000CanadaThe acquisition (by subsidiary into step-down subsidiary) constitutes a RPT between two wholly-owned subsidiaries, exempted under Regulation 23(5) of LODR Regulations. The transaction shall be undertaken at arm’s length basis.Except as step-down subsidiary of the Company, the promoter / promoter group/ group companies of the Company do not have any interest in Mantra. Turnover for FY 2023-2024 is for period November 06, 2023 till March 31, 2024.